Usability of Andago V2.0 in Gait Rehabilitation of Stroke Patients
NCT02735460
Brain Diseases, Brain Ischemia
Zihlschlacht, Switzerland
View Trial DetailsNCT Number: NCT06420011
FAITH study is a multicentre retrospective analysis study that aims to understand the burden of ICH related to FXa inhibitors and the current treatment approaches in country/countries where specific reversal agents are not available yet. The results of this analysis will improve our understanding of FXa inhibitor-related ICH, its socioeconomic impact and factors associated with negative outcomes in real-world settings. The insights gained can inform clinical decision making and potentially lead to strategies to optimise the use of FXa inhibitors, increase the availability of specific reversal agents and improve patient safety and outcomes.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Research Site, Buenos Aires, Argentina
FAITH is a retrospective, non-interventional, multicentre cohort study that will retrieve the data from medical records of adult patients who were hospitalised with confirmed diagnosis of ICH while being treated with FXa inhibitors. The primary objectives of the study is to describe the characteristics and hospital outcomes of hospitalised patients with FXa inhibitors-related ICH in real-world settings. Data of consecutive patients admitted on or after 1 January 2021 and by 30 June 2023 will be retrieved. The index date is defined as the date of hospital admission.The identification of ICH will be based on the CT/MRI scan records and according to the ICD-10-CM diagnosis code. To establish the causal relation between FXa and ICH, the study will include only patients who were determined in the medical records to have taken oral FXa inhibitors.The historical data will be followed up from the index date (the date of hospital admission) until the earliest date of death, lost to follow-up or up to 6 months.The 6-month follow-up period will allow for the assessment of the disability rate and the need for supportive care among survivors.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Index day (Date of hospitalization) to 24hours
Age of the patients at the time of hospital admission (years) is recorded on Index day within 24 hours of hospitalization
Time frame: Index day (Date of hospitalization) to 24hours
Race (Middle Eastern, Asian, other) of the eligible patients is collected
Time frame: Index day (Date of hospitalization) to 24hours
Sociodemographic characteristics like Sex (Male or Female) of the eligible patients is recorded on Index day
Time frame: Index day (Date of hospitalization) to 24hours
Sociodemographic characteristics like nationality of the eligible patients info is collected on Index day
Time frame: Index day (Date of hospitalization) to 24hours
Comorbidities info of the eligible patients is recorded on Index day
Time frame: Index day (Date of hospitalization) to 24hours
Clinical characteristics like BMI in Kg/m2 of the eligible patients is recorded on Index day
Time frame: Time of last Fxa inhibitor dose to the time of hospital admission of maximum 24 hours
At index date the following FXa inhibitor characteristics will be described :
Indication ,type and dose pf FXa Inhibitor
Time frame: Index day to 1 week
The primary ICH characteristics like type, site and presence of multicompartment haemorrhage during hospitalisation from Index date to 24hours
Time frame: Index day to 24hours
The GCS is scored between 3 and 15. 3 being the worst and 15 the best. It is composed of three parameters: best eye response (E), best verbal response (V), and best motor response (M)
Time frame: Index day to 24 hours
mRS score recorded within 24 hours on Index date The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or others causes of neurological disability. It is scored from: 0=No symptoms at all
6=death
Time frame: Index date up to 24 hours
NIHSS score recorded within 24 hours on the Index date
Scores range from 0 to 42, with higher scores indicating greater severity. Stroke severity may be stratified on the basis of NIHSS scores as follows:
Very Severe: >25 Severe: 15 - 24 Mild to Moderately Severe: 5 - 14 Mild: 1 - 5
Time frame: Index day to 24 hours
Haematoma volume based on baseline Imaging scans taken within 24 hours on the index date
Time frame: Index day to 72 hours
BP at Index date during hospital admission and in 6, 24, and 72 hours
Time frame: Index day to 1 Week
Antihypertensive treatment patterns during hospitalisation from Index date to 1 week
Time frame: Index date up to the death event during hospital stay (maximum 1 week)
Number of patients died between index date (date of hospitalization) to Hospital discharge (maximum of 1 week)
Time frame: Index date up to 30 days
Number of patients died between index date (date of hospitalization) up to 30 days
Time frame: Index date up to 3 months
Number of patients died between index date (date of hospitalization) up to 3 months
Time frame: Index date up to 6 months
Number of patients died between index date (date of hospitalization) up to 6 months
Time frame: Hospital discharge to Maximum of 6 months
During the period from the hospital discharge date up to death event or 6 months, whichever occurs first, the following type of hospital discharge disposition will be described for survivors like Home, inpatient rehabilitation facility, nursing home, other hospitals/medical centres
Time frame: Baseline (which is the date of hospitalization i.e. Index date) to a maximum of 24 hours
Time between the onset of the bleeding symptoms to admission of patient in hospital in hours.
Time frame: Index day (Date of hospitalization) to Maximum of one hour
Time between patient hospital admission to the performing of Imaging scan in minutes, less than 1 hour
Time frame: Index day (Date of hospitalization) to Maximum of one hour
Time between patient hospital admission to start of the any haemostatic therapy in minutes, in less than 1 hour
Time frame: Index day to maximum of 1 week
The length of ICU stay of eligible patients in days from Index day to maximum of 1 week
Time frame: Index day to maximum of 1 week
The length of hospitalisation of eligible patients in days from Index day to maximum of 1 week
Time frame: At hospital discharge (Maximum of 1 week from Index day)
At hospital discharge (Maximum of 1 week from Index day) Modified Rankin Score (mRS) will be described
Functional outcome assessed with the modified Rankin Scale (mRS) at hospital discharge .The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered of stroke or other causes of neurological disability. It is scored from:
0=No symptoms at all
1=No significant disability, 2=Slight disability 3=Moderate disability 4=Moderately severe disability 5=Severe disability 6=death
Time frame: Index day to 3 months
At three months, after the index event (date of hospital admission) Modified Rankin Score (mRS) will be described.
Time frame: Index date to 6 months
From the index date to 6 months the following HCRU will be described:
Need for supportive medical care ,type of supportive care (including rehabilitation services), inpatient rehabilitation, outpatient rehabilitation, including occupational therapists, speech and language pathologists, dietician, nurse, adaptive equipment, everything else.
Time frame: Hospital discharge up to 6 months
From the patient hospital discharge up to 6 months the following HCRU will be described:
Number of inpatient readmissions after discharge and up to 6 months, Type of ward, Number of days of hospitalization Reason for readmission and Medications.
Time frame: Index day to Maximum of 6 months
At six months after the index event (date of hospital admission) Modified Rankin Score (mRS) will be described.
AstraZeneca
Industry
A Real-World, Observational, Multicentre Retrospective Analysis to Evaluate the Clinical Characteristics, Medical Management and Outcomes of Hospitalised Patients With Factor XA Inhibitor-Related InTracranial Haemorrhage (FAITH)
Acronym: FAITH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02735460
Brain Diseases, Brain Ischemia
Zihlschlacht, Switzerland
View Trial DetailsNCT07553416
Brain Diseases, Brain-Computer Interfaces
Beijing, Beijing Municipality, China
View Trial DetailsNCT05970224
Brain Diseases, Cardiovascular Diseases
Ghent, East Flanders, Belgium
View Trial DetailsNCT06635564
Bleeding Disorder, Brain Diseases
Vienna, Austria
View Trial Details